Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
- 18 February 2003
- journal article
- Published by Springer Nature in Leukemia
- Vol. 17 (2) , 458-460
- https://doi.org/10.1038/sj.leu.2402811
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationBlood, 2002
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemiaBlood, 2001
- Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reactionEuropean Journal of Haematology, 2001
- Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationBone Marrow Transplantation, 2001